Back to top
more

Denali Therapeutics (DNLI)

(Delayed Data from NSDQ)

$15.43 USD

15.43
1,122,303

+0.47 (3.14%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for DNLI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Denali Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,035 1,336 865 1,470 415
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 30 36 32 26 15
Total Current Assets 1,064 1,372 897 1,496 430
Net Property & Equipment 46 44 39 41 47
Investments & Advances 0 0 425 33 40
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 18 13 12 2 3
Total Assets 1,154 1,460 1,404 1,604 553
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 9 3 5 1 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 69 67 53 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 294 320 71 43
Total Current Liabilities 78 364 378 72 45
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 1 5 318 44
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 123 418 442 454 158
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 2 2 1
Capital Surplus 2,145 2,019 1,608 1,504 819
Retained Earnings -1,116 -971 -645 -354 -426
Other Equity 1 -7 -3 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,031 1,042 962 1,151 395
Total Liabilities & Shareholder's Equity 1,154 1,460 1,404 1,604 553
Total Common Equity 1,031 1,042 962 1,151 395
Shares Outstanding 138.80 135.80 122.10 119.90 96.00
Book Value Per Share 7.43 7.68 7.88 9.60 4.11

Fiscal Year End for Denali Therapeutics Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,035 1,109 1,191 1,288
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 30 34 33 37
Total Current Assets NA 1,064 1,143 1,224 1,325
Net Property & Equipment NA 46 48 40 42
Investments & Advances NA 0 8 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 18 11 14 14
Total Assets NA 1,154 1,237 1,306 1,409
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 9 1 9 2
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 69 36 36 77
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 27 18 306
Total Current Liabilities NA 78 71 69 391
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 123 118 119 443
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 2 2 2 2
Capital Surplus NA 2,145 2,114 2,084 2,048
Retained Earnings NA -1,116 -997 -897 -1,081
Other Equity NA 1 -1 -1 -3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,031 1,118 1,187 967
Total Liabilities & Shareholder's Equity NA 1,154 1,237 1,306 1,409
Total Common Equity 0 1,031 1,118 1,187 967
Shares Outstanding 139.10 138.80 138.20 136.80 136.60
Book Value Per Share 0.00 7.43 8.09 8.68 7.08